证券代码：300391 证券简称：长药退 公告编号：2026-028 长江医药控股股份有限公司 关于聘请主办券商的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 一、聘请主办券商的情况说明 长江医药控股股份有限公司（以下简称"公司"）于2026年3月12日收到深 圳证券交易所（以下简称"深交所"）《关于长江医药控股股份有限公司股票终 止上市的决定》（深证上〔2026〕254号），深交所决定终止公司股票上市交易。 公司股票终止上市后，将转入全国股转公司代为管理的退市板块进行转让。 根据《深圳证券交易所创业板股票上市规则》《关于退市公司进入退市板块挂牌 转让的实施办法》的相关规定，公司应聘请证券公司，委托其提供进入全国股转 公司代为管理的退市板块挂牌转让服务，并授权其办理证券交易所市场的股份退 出登记、股份重新确认、退市板块的股份初始登记、提供股份转让服务等事宜。 保证公司股票在摘牌之日起四十五个交易日内可以转让。 公司股票终止上市后的股份确权、登记和托管手续及具体安排等，公司将另 行公告。请投资者关注公司聘请的主办券商后续刊登在全国中小企业股份转让系 统指定 ...

证券代码：300391 证券简称：长药退 公告编号：2026-027 1、长江医药控股股份有限公司（以下简称"公司"）股票于退市整理期届 满的次一交易日摘牌，公司股票终止上市。 2、公司股票于2026年3月20日进入退市整理期，退市整理期为十五个交易 日，预计最后交易日期为2026年4月10日。本公告披露日（2026年3月26日）为 第五个交易日，剩余十个交易日，交易期满将被终止上市。敬请投资者审慎投 资、注意风险。 3、公司股票在退市整理期交易期间，公司不筹划或实施重大资产重组。 4、请投资者、证券公司等市场主体在股票摘牌前及时了结股票质押式回购、 约定购回、融资融券、转融通等业务。 5、对于将在股票摘牌后至完成全国中小企业股份转让系统有限责任公司依 托原证券公司代办股份转让系统设立并代为管理的两网公司及退市公司板块 （以下简称"退市板块"）初始登记期间到期的司法冻结业务，建议有权机关 在股票摘牌前通过原协助执行渠道提前办理续冻手续。 公司于2026年3月12日收到深圳证券交易所（以下简称"深交所"）《关于 长江医药控股股份有限公司股票终止上市的决定》（深证上〔2026〕254号）， 深交所决定终止公司股票 ...

2、公司股票于2026年3月20日复牌并进入退市整理期，退市整理期为15个交 易日，预计最后交易日期为2026年4月10日。敬请投资者审慎投资、注意风险。 3、公司股票在退市整理期交易期间，公司不筹划或实施重大资产重组。 证券代码：300391 证券简称：*ST 长药 公告编号：2026-026 长江医药控股股份有限公司 关于公司股票进入退市整理期交易首日的风险提示公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 特别提示： 1、长江医药控股股份有限公司（以下简称"公司"或"长药控股"）股票 于退市整理期届满的次一交易日摘牌，公司股票终止上市。 三、退市整理期风险提示公告的披露安排 4、请投资者、证券公司等市场主体在股票摘牌前及时了结股票质押式回购、 约定购回、融资融券、转融通等业务。 5、对于将在股票摘牌后至完成全国中小企业股份转让系统有限责任公司依 托原证券公司代办股份转让系统设立并代为管理的两网公司及退市公司板块（以 下简称"退市板块"）初始登记期间到期的司法冻结业务，建议有权机关在股票 摘牌前通过原协助执行渠道提前办理续冻手续。 公司于2026年3月 ...

Core Viewpoint - The article discusses the administrative penalties imposed on Changjiang Pharmaceutical Holdings Co., Ltd. (*ST Changyao) due to false disclosures in its annual reports from 2021 to 2023, leading to significant fines and the termination of its stock listing [1][25]. Group 1: Company Violations - From 2021 to 2023, *ST Changyao's subsidiary companies fabricated inventory and sales documents, resulting in inflated revenues of CNY 215.32 million, CNY 283.74 million, and CNY 233.63 million, which accounted for 9.12%, 17.57%, and 19.51% of the reported revenues for those years respectively [3][4]. - The total inflated profit for the same period was CNY 56.40 million, CNY 63.38 million, and CNY 43.71 million, representing 35.62%, 88.23%, and 6.42% of the reported profit totals [3][4]. Group 2: Responsible Individuals - A total of 14 individuals were held accountable for the violations, including key figures such as: - Luo Ming, who was directly responsible for the financial misconduct and received a lifetime ban from the securities market along with a fine of CNY 5 million [11]. - Yang Zhenghui, who was fined CNY 3 million and banned for 10 years due to serious violations [11]. - Other individuals received fines ranging from CNY 150,000 to CNY 300,000 for their roles in the false reporting [13][14][15][16][17][18][19][20][21][22][23][24]. Group 3: Stock Termination - Due to the continuous false disclosures in its annual reports, *ST Changyao's stock will be forcibly delisted, as it violated the Shenzhen Stock Exchange's rules regarding significant misconduct [25]. - The company received a notice of termination of its stock listing on March 12, 2026, with trading expected to cease by April 10, 2026 [25].

证券代码：300391 证券简称：*ST 长药 公告编号：2026-024 长江医药控股股份有限公司 关于累计诉讼、仲裁事项的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 2026年3月17日，长江医药控股股份有限公司（以下简称"公司"、"长药 控股"）收到中国银行股份有限公司固原支行起诉长药控股及子公司宁夏长药良 生制药有限公司、湖北长江星医药股份有限公司、罗明、张莉的诉讼文书，涉及 的诉讼金额36,988,615.69元。截至本公告披露日，除已经披露的诉讼、仲裁事 项外，公司及子公司连续十二个月内累计涉及的诉讼、仲裁事项涉案金额合计约 5,145.04万元，占最近一期经审计净资产绝对值11.89%。现将有关情况公告如下： 3、原告新疆国晟企诚新能源有限公司与被告一河北羿珩科技有限责任公司、 被告二长江医药控股股份有限公司买卖合同纠纷案。 原告与被告一存在买卖合同关系。诉讼请求：确认原告与被告一签订的《设 备采购安装合同》关于第二条光伏组件自动化生产线设备的买卖及安装等内容已 于2025年10月10日解除；判令被告一返还原告预付的设备款项524万元及利 ...

证券代码：300391 证券简称：*ST 长药 公告编号：2026-025 长江医药控股股份有限公司 关于收到《行政处罚决定书》的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 长江医药控股股份有限公司（曾用名康跃科技股份有限公司，以下简 称"公司"、"*ST 长药"或"长药控股"）于 2025 年 11 月 7 日收到中国证 券监督管理委员会（以下简称"中国证监会"）下发的《立案告知书》，因公司 涉嫌定期报告等财务数据虚假记载，根据《中华人民共和国证券法》《中华人民 共和国行政处罚法》等法律法规，中国证监会决定对公司立案。具体内容详见公 司于 2025 年 11 月 7 日在巨潮资讯网披露的《关于公司收到中国证券监督管理 委员会立案告知书暨风险提示的公告》。 2025 年 12 月 26 日，公司及相关当事人收到中国证监会下发的《行政处罚 事先告知书》,具体内容详见公司于 2025 年 12 月 27 日披露的《关于公司及相 关人员收到<行政处罚事先告知书>的公告》。 2026 年 1 月 23 日，公司收到中国证监会下发的《行政处罚决定书》,具体 内容 ...

Core Viewpoint - *ST Changyao has been notified by the Shenzhen Stock Exchange that its stock will be delisted due to serious violations, including financial fraud and significant operational risks [2][4][5]. Group 1: Company Announcement and Stock Status - On March 12, *ST Changyao announced that it received a decision from the Shenzhen Stock Exchange to terminate its stock listing, with trading resuming on March 20 and entering a delisting preparation period of fifteen trading days, expected to end on April 10 [2]. - As of the last quarter of the previous year, *ST Changyao had a total of 14,233 shareholders, with its stock price at 0.92 yuan per share and a total market value of 320 million yuan [3]. Group 2: Financial Misconduct and Investigations - The company has been under investigation since November last year for suspected false reporting of financial data. In January, it received an administrative penalty notice from the China Securities Regulatory Commission [4]. - The investigation revealed that from 2021 to 2023, *ST Changyao inflated its reported revenue by 215 million yuan, 284 million yuan, and 234 million yuan, accounting for 9.12%, 17.57%, and 19.51% of the disclosed revenue for those years, respectively [4]. - The inflated profit totals were 56.4 million yuan, 63.4 million yuan, and 43.7 million yuan, representing 35.62%, 88.23%, and 6.42% of the disclosed profit totals for the respective years [4]. Group 3: Operational and Financial Risks - In addition to financial fraud, *ST Changyao faces multiple risks, including declining performance, overdue debts, lawsuits, frozen accounts, and significant tax arrears. As of the end of last year, the company had over 1.1 billion yuan in interest-bearing liabilities, with 390 million yuan overdue [6]. - The company also failed to reasonably recognize losses related to a project in 2022, leading to an inflated profit of 4.55 million yuan, which accounted for 6.34% of the disclosed profit for that year [5]. Group 4: Regulatory Environment and Market Impact - Since the beginning of the year, four listed companies have faced delisting or are in the delisting process due to serious violations. This includes *ST Lifang, which received a delisting notice in February [7]. - The regulatory environment is becoming increasingly stringent, with a zero-tolerance policy for serious violations, aiming to enhance market integrity and deter misconduct among key stakeholders [7].

Macro Dynamics - The National Industrial Information Security Development Research Center issued a risk warning regarding the application of OpenClaw in the industrial sector, highlighting potential security risks such as unauthorized access and information leakage due to inadequate control measures [2] Aerospace Products - Multiple new aerospace products were showcased at the 2026 Shanghai Commercial Aerospace Conference, including a rollable flexible solar wing, which is a key energy supply component for satellites, promising enhanced performance and longevity [3] Financial Institutions - Agricultural Bank reported a balance of 7.92 trillion yuan in loans to private enterprises as of the end of February 2026, with 8.58 million clients, and a balance of 4.13 trillion yuan in loans to small and micro enterprises [7] Market Data - The Shanghai Composite Index fell by 0.1%, while the coal and chemical sectors showed strength, with several stocks reaching their daily limit [9] - The financing balance of the two markets increased by 54.22 billion yuan, with the Shanghai Stock Exchange reporting a balance of 13,359.8 billion yuan [12] Company Dynamics - China Electric Power Construction signed an EPC contract worth approximately 139.62 billion yuan for a solar-storage project in Abu Dhabi, with a total installed capacity of 2.1 GW and 7.75 GWh [13][14] - Boss Electric launched the world's first AI cooking glasses at AWE 2026, integrating AI technology to assist users in cooking processes [15] - Inspur announced the release of its first self-developed 400G lossless high-speed network, scaleFabric, marking a significant advancement in domestic data center technology [16] - *ST Chang Pharmaceutical received a decision for stock delisting from the Shenzhen Stock Exchange, with trading set to resume on March 20, 2026 [17] - Aishi Technology completed a $300 million Series C financing round, marking the largest single financing in China's video generation sector to date [18] - Li Auto is considering a share buyback of its Hong Kong stock, with discussions ongoing regarding the proportion and total amount [19]

Core Viewpoint - The announcement from the Shenzhen Stock Exchange indicates that Changjiang Pharmaceutical Holdings Co., Ltd. will have its stock delisted due to false disclosures in its annual reports from 2021 to 2023 [2][4]. Summary by Sections Announcement of Delisting - On March 12, the Shenzhen Stock Exchange announced the termination of the stock listing for Changjiang Pharmaceutical Holdings Co., Ltd. [1] - The stock will enter a delisting preparation period starting March 20, 2026, lasting for fifteen trading days, with the final trading day expected to be April 10, 2026 [5]. Regulatory Actions - The company received an administrative penalty decision from the China Securities Regulatory Commission on January 23, 2026, citing false disclosures in its annual reports [2][7]. - The company violated specific rules outlined in the Shenzhen Stock Exchange's listing regulations, leading to the decision for delisting [4]. Financial Misconduct - From 2021 to 2023, the company inflated its reported revenues and profits through false documentation, including fake inventory and sales records, resulting in significant discrepancies in financial reporting [8]. - The inflated figures included an increase in reported revenue of 215.32 million yuan, 283.74 million yuan, and 233.63 million yuan for the respective years, representing 9.12%, 17.57%, and 19.51% of the disclosed revenue [8]. - The inflated profit totals were 56.40 million yuan, 63.38 million yuan, and 43.71 million yuan, accounting for 35.62%, 88.23%, and 6.42% of the disclosed profit for the respective years [8]. Post-Delisting Procedures - After delisting, the company's stock will be managed by the National Equities Exchange and Quotations (NEEQ) for transfer in the delisting sector [6]. - The company is required to hire a securities firm to assist with the delisting process and related transactions [6].

证券代码：300391 证券简称：*ST 长药 公告编号：2026-023 长江医药控股股份有限公司 关于公司股票进入退市整理期交易的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 特别提示： 1、长江医药控股股份有限公司（以下简称"公司"或"长药控股"）股票 于2026年3月20日复牌并进入退市整理期，退市整理期为十五个交易日，预计最 后交易日期为2026年4月10日。公司股票于退市整理期届满的次一交易日摘牌并 终止上市。 2、公司股票在退市整理期交易期间，公司将不筹划或实施重大资产重组。 3、请投资者、证券公司等市场主体在股票摘牌前及时了结股票质押式回购、 约定购回、融资融券、转融通等业务。 公司于2026年3月12日收到深圳证券交易所（以下简称"深交所"）《关于 长江医药控股股份有限公司股票终止上市的决定》（深证上〔2026〕254号）， 深交所决定终止公司股票上市交易。根据《深圳证券交易所创业板股票上市规则》 的相关规定，公司股票将于2026年3月20日起进入退市整理期交易。 现将公司股票在退市整理期交易的相关安排公告如下： 一、公司股票在退市整理 ...